Positive high-level results from the final overall survival (OS) analysis of the FLAURA2 Phase 3 clinical study (NCT04035486) showed that osimertinib (Tagrisso®; AstraZeneca), a third-generation, irreversible EGFR-TKI, with the addition of pemetrexed (Alimta®; Eli Lilly & Co) and platinum-based chemotherapy (Carboplatin or Cisplatin), demonstrated a statistically significant and clinically meaningful improvement in the key secondary endpoint of OS compared to osimertinib monotherapy for patients with 1st-line locally advanced or metastatic epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC).
Lung cancer is the leading cause of cancer death among men and women, accounting for about one-fifth of all cancer deaths.[1] Lung cancer is broadly split into small cell lung cancer or NSCLC, the latter accounting for 80-85% of cases.[1][2] Approximately 75% of people are diagnosed with advanced NSCLC.[3]
Some lung cancers are caused by mutations in the Deoxyribonucleic acid (DNA), which, if known, can help physicians decide the best treatment for their patients. One type of mutation can occur in the gene that produces a protein on the surface of cells called Epidermal Growth Factor Receptor (EGFR). About 10-15% of patients diagnosed with NSCLC in the US and Europe, and 30-40% of patients in Asia have EGFRm NSCLC.[4][5][6]
While EGFR-tyrosine kinase inhibitors (TKI) have significantly improved outcomes in the 1st-line setting, mechanisms of resistance and disease progression are extremely common, and a significant unmet need exists in later-line settings for effective and well-tolerated treatment options.[7][8][9][10]
Study
The FLAURA2 trial is a randomized, open-label, multi-centre, global Phase 3 clinical study in the 1st-line treatment of patients with locally advanced (Stage IIIB-IIIC) or metastatic (Stage IV) EGFRm NSCLC. Patients were treated with osimertinib 80mg QD oral tablets with the addition of chemotherapy (pemetrexed (500mg/m2) plus cisplatin (75mg/m2) or carboplatin (AUC5) every three weeks for four cycles, followed by osimertinib with pemetrexed maintenance every three weeks.
The trial enrolled 557 patients in more than 150 centers across more than 20 countries, including in the US, Europe, South America and Asia. The primary endpoint is PFS with OS as the key secondary endpoint.
Overall survival Analysis
The final OS analysis demonstrates consistent survival benefit as previously reported in the interim OS results, and builds on the previously presented primary endpoint data, which demonstrated the longest-reported median progression-free survival (PFS) in this setting.
“When treating lung cancer, the aim is to both prolong survival and improve the patient experience, especially in 1st-line where treatment duration can be long and many patients remain active,” noted Pasi A. Jänne, MD, PhD, Senior Vice President for Translational Medicine and thoracic medical oncologist at Dana-Farber Cancer Institute and principal investigator for the FLAURA2 trial.
“These positive results support osimertinib, either as monotherapy or in combination with chemotherapy, as standard of care for patients with 1st-line advanced EGFR-mutated lung cancer and reinforce the meaningful benefit of the combination in the current clinical setting. The observed survival benefit is particularly impressive given that FLAURA2 did not impose any restrictions on the choice of subsequent treatment after disease progression,” Jänne continued.
Extensive evidence
“These exciting overall survival results add to the extensive evidence supporting osimertinib as the backbone therapy in EGFR-mutated lung cancer, demonstrating that osimertinib plus chemotherapy can significantly extend survival in the 1st-line advanced setting, in addition to prior trials showing survival benefits as monotherapy in both early stage and advanced disease,” said Susan Galbraith, Executive Vice President, Oncology Hematology R&D, AstraZeneca.
“With its strong survival benefit and tolerable safety profile, this combination has the potential to help patients live longer while maintaining their quality of life on treatment,” she added.
With longer follow up, the safety profile of osimertinib plus chemotherapy continues to be manageable and consistent with the established profiles of the individual medicines. Adverse event (AE) rates were higher in the osimertinib plus chemotherapy arm, driven by well-characterised chemotherapy-related AEs. Discontinuation rates due to AEs and on-target toxicities were low in both arms of the trial.
These data will be presented at a forthcoming medical meeting and shared with global regulatory authorities.
Additional studies
There is an extensive body of evidence supporting the use of osimertinib in EGFRm NSCLC. Osimertinib is the only targeted therapy shown to improve patient outcomes in early-stage disease in the NeoADAURA (NCT04351555) and ADAURA (NCT02511106) Phase 3 trials, locally advanced stages in the LAURA (NCT03521154) Phase 3 trial and late-stage disease in the FLAURA (NCT02296125) and FLAURA2 (NCT04035486) Phase 3 clinical studies.
Osimertinib is also being investigated in the early-stage adjuvant resectable setting in the ADAURA2 Phase III trial.
Regulatory landscape
Osimertinib plus chemotherapy is approved in more than 80 countries, including the US, EU, China and Japan, based on the FLAURA2 Phase 3 trial.
Clinical trials
A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2) – ClinicalTrials.gov ID NCT04035486
AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLAURA) – ClinicalTrials.gov ID NCT02296125
A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer (NeoADAURA) – ClinicalTrials.gov ID NCT04351555
AZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy. (ADAURA)
ClinicalTrials.gov ID NCT02511106
A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer (LAURA) – ClinicalTrials.gov ID NCT03521154
Highlights of Prescribing Information
Osimertinib (Tagrisso®; AstraZeneca)[Prescribing Information]
Pemetrexed (Alimta®; Eli Lilly & Co)[Prescribing Information]
References
[1] World Health Organization. International Agency for Research on Cancer. Lung Cancer Fact Sheet. Online. Last accessed on July, 19, 2025.
[2] American Cancer Society. What Is Lung Cancer? Online. Last accessed on July, 19, 2025.
[3] Chen HJ, et al. Long-term survival of advanced lung adenocarcinoma by maintenance chemotherapy followed by EGFR-TKI. Medicine. 2021;100(6):e24688.
[4] Keedy VL, et al. American Society of Clinical Oncology Provisional Clinical Opinion: Epidermal Growth Factor Receptor (EGFR) Mutation Testing for Patients with Advanced Non-Small-Cell Lung Cancer Considering First-Line EGFR Tyrosine Kinase Inhibitor Therapy. J Clin Oncol. 2011:29;2121-27.
[5] Szumera-Ciećkiewicz A, et al. EGFR Mutation Testing on Cytological and Histological Samples in Non-Small Cell Lung Cancer: a Polish, Single Institution Study and Systematic Review of European Incidence. Int J Clin Exp Pathol. 2013;6:2800-2812.
[6] Ellison G, et al. EGFR Mutation Testing in Lung Cancer: a Review of Available Methods and Their Use for Analysis of Tumour Tissue and Cytology Samples. J Clin Pathol. 2013;66:79-89.
[7] Chen R, et al. Emerging therapeutic agents for advanced non-small cell lung cancer. J Hematol Oncol. 2020;13(1):58.
[8] Majeed U, et al. Targeted therapy in advanced non-small cell lung cancer: current advances and future trends. J Hematol Oncol. 2021;14(1):108.
[9] Morgillo F, et al. Mechanisms of resistance to EGFR-targeted drugs: lung cancer. ESMO Open. 2016;1(3):e000060.
[10] Han B, et al. Efficacy of pemetrexed-based regimens in advanced non-small cell lung cancer patients with activating epidermal growth factor receptor mutations after tyrosine kinase inhibitor failure: a systematic review. Onco Targets Ther. 2018;11:2121-2129.
Featured image: Lung radiography | Doctor examining a lung radiography. Photo courtesy: © 2018 – 2025 Fotolia/Adobe. Used with permission
DOI





